Glial cell line-derived neurotrophic factor (GDNF) was identified in 1993 (Lin et al., 1993), and since then it has been considered a strong survival factor for dopaminergic neurons of the nigrostriatal pathway that degenerate in Parkinson’s disease (PD). This has led to the proposal of GDNF as a potential therapy to slow down, halt or reverse neurodegeneration in PD. Thus, the link GDNF-PD is quite instantaneous, and difficult to keep away from. In this chapter we want to explore less common perspectives in this relationship, and we propose to look at this association from unconventional/emerging points of view, one might say, beyond the typical top10. We will discuss some aspects of PD pathophysiology and alternative therapeutic approaches in PD from a GDNF point of view.
Epidemiological studies show a greater prevalence of PD in men than in women, and there are also gender differences in the progression of the symptoms and responses to L-DOPA treatment (Miller & Cronin-Golomb, 2010). Although the reasons for these gender differences in PD remain to be elucidated, there is growing evidence that estrogen may play a role in this phenomenon. We will present evidences that GDNF may account for the neuroprotection of dopaminergic neurons promoted by estrogen and thereby help to explain the lower incidence of PD in women.
Neuroinflammation is recognized as a major factor in PD pathogenesis, and increasing evidence suggest that microglia is the main source of inflammation contributing to dopaminergic degeneration (Tansey & Goldberg, 2009). Astrocytes, on the other hand, can act as physiological regulators preventing excessive microglial responses (Lynch, 2009). We propose that GDNF can be a key player in astrocytes modulation of microglia activation in the
Several attempts have been made to increase GDNF at lesion sites aiming at neuroprotection/neuroregeneration. However, the delivery of GDNF to the central nervous system (CNS) is challenging because GDNF is unable to cross the blood–brain barrier. One possibility to overcome this limitation is to conjugate or fuse GDNF with viral proteins, antibodies for transferrin or insulin receptors, or with a fragment of the tetanus toxin, which enable it to cross the blood–brain barrier. Another option is to use molecules that induce GDNF expression or enhance its signaling, and we will emphasize natural compounds. These molecules may prove to be an alternative therapeutic option for PD as herbal extracts are increasingly being reported to be neuroprotective in animal models of PD. Unconventional ways to increase GDNF levels in the brain include dietary manipulations, physical exercise, cognitive stimulation or acupuncture, and these may represent novel drug-free and non-invasive approaches for disease prevention and treatment, an issue that will also be addressed.
Neurodegenerative diseases are puzzling and there is still a long way before we can have answers to all our questions and concerns. In this chapter we hope to disclose new links between GDNF and the pathophysiology of PD, and bring together data that enable a new view on the protective actions of several compounds and lifestyles capable of modulating GDNF levels, which may have therapeutic implications. We believe that this chapter may help in some way to draw attention to new directions of research, and to explore the GDNF-PD route with new eyes.
2. Gender differences in PD
Epidemiological studies have suggested gender differences in PD risk, symptom severity, and treatment outcome (Miller & Cronin-Golomb, 2010). A higher prevalence of PD in men (Baldereschi et al., 2000; Kurtzke & Goldberg, 1988; Marder et al., 1996; Mayeux et al., 1992; Wooten et al., 2004), with a two-fold greater relative risk of PD in men than women (Gillies & McArthur, 2010b), were also reported. In what concerns symptom severity, males present worse rigidity, more frequent symptoms such as writing difficulties, fumblingness, speech and gait problems, whereas women exhibit more levodopa-induced dyskinesia (Miller & Cronin-Golomb, 2010). In addition, sex differences in response to anti-parkinsonism medications have also been reported (Brann et al., 2007). There is greater levodopa bioavailability in women, with higher plasma concentration, so the mean levodopa dosage is lower for women than for men (reviewed by Shulman, 2007). Furthermore, the treatment with levodopa promotes more significant improvements of motor function in women than in men (reviewed by Brann et al., 2007).
While the reason for the sex differences in PD remains to be elucidated, there is growing evidence that estrogen may play a neuroprotective role. This hypothesis is also supported by data showing that shorter exposures to estrogen during life, including fertile life length shorter than 36 years, and cumulative length of pregnancies longer than 30 months, are associated with younger age at onset of PD. In contrast, the use of postmenopausal estrogen replacement therapy seems to reduce the risk of developing the disease (Currie et al., 2004). Also supportive of the protective role of estrogen are data showing that situations corresponding to low endogenous estrogen levels, such onset of menses and menopause or withdrawal of hormone replacement therapy, result in a worsening of parkinsonian symptoms (Gillies & McArthur, 2010b). In contrast, the results obtained in gonadectomized adult male rats and mice exposed to testosterone and dihydrotestosterone indicate that androgens repress the expression of a midbrain dopaminergic phenotype (M.L. Johnson et al., 2010).
In addition to the pro-dopaminergic action of estrogen, an increasing amount of evidence suggests an inherent sex dimorphism in the nigrostriatal pathway.
2.1. Estrogen-mediated neuroprotection in PD models
17β-estradiol, the estrogen stereoisomer with female hormone activity and with high affinity to estrogen receptors, has been shown, both
Most studies on the neuroprotective effects of 17β-estradiol have been developed in female rodents, and the results on the protective effects of estrogen in male rodents are still controverse (Bourque et al., 2009; Murray et al., 2003). Both the dose of the hormone and the time of administration in relation to the lesion induction seem to be determinant to the results achieved. Although there are reports showing that 17β-estradiol therapy reduces dopaminergic lesion in females but not in males (Bourque et al., 2009; B. Liu & Dluzen, 2007), recent results from our group show that 17β-estradiol, administered to male rats at a dose regimen that mimics the female physiological levels of the steroid protects dopaminergic cells from a mild lesion induced by intrastriatal administration of 6-OHDA (De Campos et al., 2010). The discrepancies between the results obtained in different studies may also be influenced by differences in the lesion model/volume, or the use of intact or gonadectomized animals, thus altering the contribution of androgens.
2.2. Estrogen receptors involved in the neuroprotection of dopaminergic neurons
The expression of estrogen receptors (ERs) in the
It is now well documented that estrogen produces its effects by classic (also called genomic) and non-classic (or non-genomic) actions. The classic pathway involves the activation of intracellular receptors and the regulation of gene transcription. The non-classical pathway is generally associated with more rapid effects (from seconds to minutes) and is initiated by the interaction of 17β-estradiol with receptors in the plasma membrane (Bourque et al., 2009). In the brain, the actions of 17β-estradiol mediated through membrane-associated receptors involve the activation of two different signaling pathways, the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol-3 kinase (PI3-K)/Akt pathway (Morissette et al., 2008).
2.3. Contribution of GDNF to estrogen-mediated neuroprotection
The interactions between 17β-estradiol and neurotrophic factors, namely the ability of the former to regulate the expression of neurotrophic factors such as brain-derived neurotrophic factor (BDNF), insulin-like growth factor-I (IGF-I), artemin, their receptors or signaling pathways, are well documented (Dittrich et al., 1999; Garcia-Segura et al., 2007; Ivanova et al., 2001; J. Kang et al., 2010; Pan et al., 2010; Pietranera et al., 2010; J. Zhou et al., 2005). The expression of GDNF is also modulated by estrogens. As mentioned above, 17β-estradiol, through membrane-associated receptors, can activate the PI3-K/Akt pathway and regulate transcription factors such as NF-kB and cAMP response element binding protein (CREB) (Bourque et al., 2009), which are known to be involved in the control of GDNF expression (Saavedra et al., 2008). 17β-estradiol induces the expression of GDNF in spinal cord astrocyte cultures, and this increase in GDNF rescues spinal motoneurons from AMPA-induced toxicity (Platania et al., 2005). In hypothalamic cultures, 17β-estradiol up-regulates the expression of GDNF in neurons but not in astrocytes (Ivanova et al., 2002). These observations suggest a region-dependent effect on the cell type responsible for GDNF production in response to 17β-estradiol, which may be related to the presence/absence of estrogen receptors in different cell types depending on their location.
The induction of GDNF expression by 17β-estradiol in hypothalamic cell cultures is not prevented by the nuclear receptor antagonist ICI 182,780, indicating that it is mediated by non-classical estrogen signaling. In contrast, it is inhibited by cAMP/PKA and calcium signaling antagonists, suggesting that intracellular calcium and cAMP/PKA signaling are required for GDNF increase in neuronal cells in response to 17β-estradiol. GDNF regulation by 17β-estradiol was also investigated in neonatal astroglial and embryonic mesencephalic neuronal cultures (Kipp et al., 2006). In this case, the up-regulation of GDNF transcription occurs in astrocytes but not in neurons, and the effect is not prevented by ICI 182,780, but is abrogated by interrupting the intracellular calcium signaling or the MAPK signal transduction system (Kipp et al., 2006). In addition, unpublished results from our group show that 17β-estradiol up-regulates GDNF levels in neuron-glia ventral midbrain postnatal cultures, and potentiates the reported L-DOPA- or H2O2-induced GDNF up-regulation in the same model (Saavedra et al., 2005, 2006). Estradiol-induced increase of GDNF levels is not blocked by ICI 182,780, and can be induced by estradiol-BSA, a membrane impermeable form, thus supporting the idea that 17β-estradiol is acting through a non-classical pathway (Fig. 1). Although GDNF up-regulation occurs in astrocytes, it is dependent on the presence of neurons indicating that neurons play a crucial role in the signaling process. GDNF neutralization and siRNA-mediated GDNF knockdown experiments clearly demonstrate the participation of this GDNF up-regulation in the neuroprotection provided by 17β-estradiol in 6-OHDA-challenged cultures (De Campos et al., 2010).
2.4. Does GDNF contribute to the antioxidant actions of estrogen?
Oxidative stress is considered an important contributor to the neurodegeneration associated with PD, and several markers of oxidative damage are increased in the
2.5. Anti-apoptotic role of estrogen
Oxidative stress can cause neuronal apoptosis (Ratan et al., 1994; Tan et al., 1998) and has been considered as one of the major causes of dopaminergic degeneration (Mochizuki et al., 1996; Przedborski & Ischiropoulos, 2005). The neuroprotection mediated by estrogen involves the modulation of apoptosis-related genes (Garcia-Segura et al., 1998; Singer et al., 1998; Vegeto et al., 1999). Sawada and colleagues (2000) studied the anti-apoptotic mechanism induced by estradiol on nigral dopaminergic neurons. They show that estradiol suppresses gene transcription through the AP-1 element, inhibits the transcription of pro-apoptotic genes, and up-regulates the anti-apoptotic Bcl-2, with the consequent reduction of caspase activation. Interestingly, GDNF is able to support the viability of postnatal nigral dopaminergic neurons and embryonic human mesencephalic neurons by inhibiting apoptotic cell death naturally occurring
2.6. Anti-inflammatory role of estrogen and dopaminergic neuroprotection
Estrogens control glial activation and the expression of inflammatory mediators implicated in neuroinflammation and neurodegeneration, such as cytokines and chemokines (reviewed by Morale et al., 2006). 17β-estradiol down-regulates glial activation promoted by MPTP in the
3. The vigilant glia
Microglia are the surveillance cells in the CNS, exquisitely sensitive to brain injury and disease, altering their morphology and phenotype to adopt an activated state in response to pathophysiological brain insults. In the adult healthy brain, the majority of microglia is in a “resting” state, monitoring for pathogens and changes in the surrounding microenvironment. Neurons express cell-surface ligands that interact with receptors on the surface of microglia to induce these highly specialized cells to adopt a resting phenotype. For example, CD200 expressed by neurons binds to its receptor CD200R on the microglial cell surface. The regulatory role of CD200-CD200R signaling has been compared to a “break” on innate immunity (X.J. Wang et al., 2007). Moderately activated microglia plays a homeostatic role in the CNS by scavenging neurotoxins, removing dying cells and cellular debris, and promoting collateral sprouting through the release of trophic factors (Block et al., 2007). The designation “activated microglia” comprises highly plastic cells with numerous functionally distinct phenotypes that are not readily apparent from either their morphology or from a limited number of cell-surface antigens that they are known to express (Perry et al., 2010).
3.1. Protective microglia
In the nigrostriatal system, activated microglia and macrophages promote axonal growth and sprouting of dopaminergic neurons after a mechanical lesion to the striatum (Batchelor et al., 1999). After striatal injury, sprouting dopaminergic fibers grow towards and surround macrophages expressing GDNF and BDNF mRNA (Batchelor et al., 1999). The dopaminergic sprouting after striatal injury was shown to involve the production of GDNF by macrophages at the wound site, since preventing GDNF expression with antisense oligonucleotides resulted in a marked decrease in the intensity of the periwound sprouting as revealed by immunohistochemistry and activity of DAT (Batchelor et al., 2000). Moreover, dopaminergic sprouting was related to a gradient of GDNF (Batchelor et al., 2002). These data clearly show that activated microglia and macrophages induce dopaminergic sprouting through synthesis of neurotrophic factors. Interleukin-1 (IL-1) is also involved in dopaminergic sprouting since IL-1 receptor knockout mice do not show neuronal sprouting after a 6-OHDA lesion (Parish et al., 2002). IL-1, produced by reactive microglia and macrophages, induces astrogliosis. Therefore, activated microglia and macrophages appear to stimulate dopaminergic sprouting both directly, by the secretion of neurotrophic factors, and indirectly by the secretion of IL-1 and the stimulation of reactive astrocytosis (Ho & Blum, 1998; Parish et al., 2002). Furthermore, a protective role of microglia in the dopaminergic system was also suggested by results showing that striatal injection of 6-OHDA increases the number of neuron/glial 2 (NG2) cells coexpressing the microglia marker Iba1 and GDNF, both in the striatum and
3.2. PD and neuroinflammation: a toxic version of microglia
Neuroinflammation is a pathological hallmark in patients and experimental models of PD. Both present the classical features of inflammation, with evidence of an uncontrolled process. Moreover, microglia may become activated early in the disease process and remain primed, responding strongly to subsequent stimuli, and thereby enhancing inflammation-induced oxidative stress and cytokine-dependent toxicity in vulnerable neuronal populations (Halliday & Stevens, 2011). In PD, for unknown reasons microglia become persistently overactivated, leading to the overproduction of cytokines (e.g. tumour necrosis factor (TNF)-α, IL-1β and IL-6), and other pro-inflammatory mediators, as well as the release of reactive oxygen species (ROS) (Y.S. Kim & Joh, 2006). A high number of activated microglia has been found in the
3.3. Role of GDNF in controlling microglia activation
Consistent with the role of microglia in the pathogenesis and progression of PD, it has been demonstrated that an attenuation of dopaminergic neurodegeneration may be achieved by regulating microglial activation. There is a good deal of evidence suggesting that astrocytes are capable of reducing the potentially damaging effects of microglia. One of the mechanisms may be through the regulation of microglial expression of the antioxidant enzyme heme oxygenase-1 (HO-1) (Min et al., 2006). Astrocytes are also able to reduce LPS-induced NOS expression and NO production by microglia (Lynch, 2009). Besides, coculture with astrocytes or exposure to astrocyte conditioned media has been shown to reduce microglial phagocytic activity, and the production of IL-12 induced by LPS or interferon (IFN)-γ (Lynch, 2009). Astrocyte-derived transforming growth factor (TGF)-β and IL-10 are known to suppress microglial activation (Y.S. Kim & Joh, 2006). Recent work from our group has shown that soluble mediators released by cultured ventral midbrain astrocytes are able to prevent microglial activation induced by the pro-inflammatory agent Zymosan A (Rocha et al., 2010). We have found that low molecular weight (< 10 kDa) astrocyte-derived soluble mediators, including metallothionein-I/II, a small astrocytic protein with protective roles in the CNS, are able to suppress microglial activation induced by 0.5 µg/mL Zymosan A (Fig. 2). However, when a higher concentration of Zymosan A was used (5 µg/mL), these low molecular weight mediators were insufficient to prevent microglial activation. Under these conditions, we found that among three neurotrophic factors expressed by midbrain astrocytes (GDNF, cerebral dopamine neurotrophic factor (CDNF) and BDNF), only GDNF was able to modulate microglial activation induced by 5 µg/mL Zymosan A. This result was confirmed using several approaches, namely GDNF neutralization experiments, GDNF silencing in astrocyte cultures, and exogenous addition of GDNF to non-conditioned astrocyte culture media. Our results also show that the action of GDNF in microglial cells depends on GDNF family receptor (GFR)α1 (Rocha et al., 2010), a component of the receptor complex that can comprise also the transmembrane Ret tyrosine kinase or the neural cell adhesion molecule (NCAM) (Ibanez, 2010). Thus, the binding of astrocyte-derived GDNF to microglial GFRα1 receptors activates intracellular signaling cascade(s) responsible for inhibiting microglial activation. Our results are in accordance with the finding that exogenous GDNF inhibits LPS-induced increase of NO production and in the number of OX-6-positive cells in the
This regulation of microglial activation by GDNF is of particular interest since GDNF is a potent neurotrophic factor for dopaminergic neurons in the nigrostriatal pathway (Duarte et al., 2007). Previous studies from our group have shown that upon neuronal injury, astrocytic expression of GDNF is increased as a neuroprotective strategy (Saavedra et al., 2006). Astrocytic GDNF up-regulation was found to involve the release of soluble mediators, namely IL-1β, that signal ventral midbrain astrocytes to increase GDNF expression (Saavedra et al., 2007). Furthermore, we have found that injured nigral neurons trigger GDNF up-regulation in striatal cells (Fig. 3), a mechanism that can be relevant to the neuroprotection of dopaminergic terminals in the striatum. Altogether, these data raise the hypothesis that the neuroprotective effect of GDNF in the nigrostriatal system can result not only from a direct effect on dopaminergic neurons, but also from an indirect action through the modulation of glial crosstalk and the neuroinflammatory cascade occurring in PD.
Interestingly, inflammatory stimuli are among the candidate signals involved in the intercellular talk that induces glial GDNF expression after injury. Indeed, elevated GDNF expression is observed in response to LPS and to the pro-inflammatory cytokines IL-1β, IL-6, TNF-α and TNF-β in C6 cells (Appel et al., 1997; Verity et al., 1998), and in U-87MG glioblastoma cells (Verity et al., 1999). In cultured astrocytes both exogenous TNF-α, via TNF receptors, and endogenously produced TNF-α induce GDNF expression suggesting that an autocrine loop contributes to the production of neurotrophic factors in response to inflammation (Kuno et al., 2006). In contrast, TNF-α, TNF-β, IL-1β and LPS repress GDNF release in SK-N-AS neuroblastoma cells (Verity et al., 1999). Therefore, it has been proposed that GDNF synthesis and release in response to inflammatory molecules may be differentially regulated in cells of glial and neuronal phenotype (Verity et al., 1999). LPS also increases GDNF secretion (McNaught & Jenner, 2000) as well as GDNF mRNA expression in rodent primary astrocyte cultures (Kuno et al., 2006; Remy et al., 2003).
suggests that repair of CNS injuries can occur through GDNF produced by activated microglia/macrophages. Summarizing, growing evidence indicates that microglial activation promotes GDNF expression, and more recent data indicate that GDNF in turn inhibits microglia reactivity which may indicate that GDNF is involved in a process that self-limits microglial neurotoxicity, thus avoiding neuronal injury. These observations lead us to propose that this process to control microglia activation via GDNF fails in PD, and highlight the importance of better understanding the mechanisms implicated in the control of microglia activation by GDNF, and whether changes in these processes occur during the progression of PD.
4. Treating PD with neurotrophic factors: the GDNF candidate
Neurotrophic factors have emerged as key factors in the survival and phenotypic differentiation of neuronal cells during development, in the maintenance of mature neurons in the adult, as well as in their protection/repair upon injury (Benn & Woolf, 2004). It was proposed that changes in the levels of neurotrophic factors, due to alterations in the synthesis, release or activity associated with aging or genetic factors, might be involved in the neuronal loss observed in neurodegenerative diseases as PD (Mattson & Magnus, 2006; Siegel & Chauhan, 2000). The last years have registered increasing interest in the application of neurotrophic factors to the therapeutic field, and PD is a neurodegenerative disease whose treatment with trophic factors has been the focus of extensive research. The potential of GDNF, the prototypical neurotrophic factor for dopaminergic neurons, as a neuroprotective and neurorestorative agent to slow down or halt PD progression, has been vastly debated in the last years (e.g. Aron & Klein, 2011; Evans & Barker, 2008; Hong et al., 2008; Peterson & Nutt, 2008; Ramaswamy et al., 2009; Vastag, 2010).
It has been proposed that those neurons more vulnerable in PD
Post-mortem studies investigating GDNF distribution in the human parkinsonian brain have yielded conflicting results (Saavedra et al., 2008), and clinical trials performed in advanced PD patients have generated quite disappointing outcomes (see below, 4.1 Clinical trials using GDNF), but many studies in animal models show that GDNF delivery can have trophic effects and restore motor function (Soderstrom et al., 2006). Additionally, GDNF is essential for the maintenance of adult nigrostriatal dopaminergic neurons and other central and peripheral nuclei affected in PD (Pascual et al., 2008). Therefore, the idea of using GDNF as a neuroprotective/neurorestorative therapy for PD is still being pursuited.
Mesencephalic astrocyte-derived neurotrophic factor (MANF), identified as selectively trophic for dopaminergic neurons
4.1. Clinical trials using GDNF
Several clinical trials have been performed using the direct intracerebral infusion of GDNF. Despite the extensive literature supporting the neuroprotective role of GDNF on the nigrostriatal pathway most of the clinical trials performed in advanced PD patients have generated rather disappointing results (Aron & Klein, 2011).
The first clinical trial consisted in a randomized controlled trial using recombinant GDNF (r-metHuGDNF, Liatermin®, Amgen) and placebo delivered monthly as bolus via an intraventricular (ICV) catheter to patients with idiopathic PD (Nutt et al., 2003). No clinical benefits were registered at doses sufficient to induce side effects, and the post-mortem analysis of one patient revelead no evidence of rescue of dopaminergic fibers in the striatum or cells in the
The overall discouraging results from these clinical trials may be related to poor diffusion of GDNF, the development of anti-GDNF antibodies, or other unindentified effects, while the different outcomes have been proposed to rely on differences in GDNF doses or catheter properties, patient cohort selection, or the choice of unsuitable endpoints, with suboptimal brain delivery of GDNF considered the major limiting factor (Aron & Klein, 2011; Sherer et al., 2006).
A phase I trial involving the delivery of neurturin, another member of the GDNF family, to the striatum of PD patients via adeno-associated virus (AAV) vector showed tolerability, safety, and also potential efficacy (Marks et al., 2008), and a phase II trial was carried out. In this clinical trial there was no significant difference in the UPDRS motor score at 12 months between patients treated with AAV2-neurturin compared with control individuals, and some patients developed tumours (Marks et al., 2010). Currently, a new trial involving the delivery of a four-fold higher dose of AAV2-neurturin to both the putamen and
4.2. The ups and downs of GDNF
Although GDNF overexpression is neuroprotective, uncontrolled GDNF levels could lead to unexpected side effects. High doses of exogenously delivered GDNF induce dyskinesias and weight loss in monkeys (Z. Zhang et al., 1997). Additionally, compensatory down-regulation of TH in response to GDNF overexpression in the nigrostriatal system has been reported, both in intact (Georgievska et al., 2004; Rosenblad et al., 2003) and lesioned (Georgievska et al., 2002) rats. An important issue with possible functional consequences that was not addressed in these studies is whether prolonged GDNF infusion alters GDNF receptors Ret, GFRα1 and/or NCAM levels. There is evidence that BDNF infusion into the hippocampus for 6 days (Frank et al., 1996), or prolonged BDNF treatment of primary cortical (Knusel et al., 1997) or hippocampal (Haapasalo et al., 2002) cultures can down-regulate TrkB receptor levels. However, more recent studies in cultured hippocampal slices argue against the possibility that sustained periods of increased BDNF levels will initiate compensatory responses at the receptor level, and suggest that chronic up-regulation of BDNF is accompanied by increased activation of the neurotrophin receptor at spine synapses (Lauterborn et al., 2009). Thus, it is relevant to assess the effect of sustained high levels of GDNF in the nigrostriatal system on GDNF receptor levels as a possible compensatory down-regulation can limit GDNF-mediated neuroprotection. A potential approach to prevent the negative consequences of chronic GDNF infusion in the brain might be to use a regulated viral vector system (Manfredsson et al., 2009). Once optimized, such a system will offer the possibility to fine-tune the therapeutic dose to each PD patient, and to quickly stop GDNF overexpression in case toxicity emerges by adjusting the administration of the controlling agent (Manfredsson et al., 2009).
Several efforts are being made to solve the problems associated with the delivery, targeting, safety, and distribution of trophic factors to the CNS, which need to be overcome before GDNF therapy for PD becomes a reality (Sherer et al., 2006). The delivery of GDNF to the CNS is challenging because GDNF is unable to cross the blood-brain barrier (Kastin et al., 2003; Kirik et al., 2004). A possibility to overcome this limitation is to conjugate or fuse GDNF with other molecules that enable it to cross the blood-brain barrier. Fusion with viral proteins (Dietz et al., 2006), conjugation with antibodies for transferrin (Albeck et al., 1997; Xia et al., 2008; Q.H. Zhou et al., 2010) or insulin (Boado & Pardridge, 2009; Boado et al., 2007) receptors, or with a fragment of the tetanus toxin (Larsen et al., 2006) provides an efficient way of delivering GDNF to the CNS. Recently, GDNF delivery to the CNS using bone marrow stem cell-derived macrophages, which are able to pass the blood-brain barrier, was proven to ameliorate MPTP-induced degeneration of TH-positive neurons and terminals, stimulate axon regeneration, and reverse hypoactivity in the open field test (Biju et al., 2010).
4.3. Inducing endogenous GDNF expression/signaling
Molecules that induce the endogenous expression of trophic factors or enhance their signaling are receiving increasing attention as alternative therapeutic options for PD. Therefore, in addition to a therapeutic tool itself, GDNF constitutes also a target for the development of new therapeutics. Interestingly, it was suggested that XIB4035, a non-peptidyl small molecule that acts as a GFRα1 agonist and mimics the neurotrophic effects of GDNF in Neuro-2A cells, might have beneficial effects for the treatment of PD (Tokugawa et al., 2003). Leucine-isoleucine (Leu-Ile), a hydrophobic dipeptide that partially resembles the site on FK506 that binds to immunophilin (Schreiber, 1991), significantly increases GDNF and BDNF levels in the conditioned medium from cultured hippocampal neurons, and protects both dopaminergic and non-dopaminergic neurons from natural cell death in low density cultures (Nitta et al., 2004). Interestingly, the effect is lost when cultures are prepared from mice lacking the
5. Complementary and alternative ways of getting GDNF?
PD patients commonly use complementary and alternative therapies, including altered diet, dietary supplements, herbal supplements, caffeine, nicotine, exercise, physical and massage therapy, melatonin, bright-light therapy and acupuncture (Lokk & Nilsson, 2010; Pecci et al., 2010; Zesiewicz & Evatt, 2009). What is the impact of these complementary and alternative therapies on GDNF levels?
5.1. Is there a GDNF diet?
Compelling evidence from epidemiological and animal studies highlights the importance of dietary factors in counteracting dopaminergic degeneration occurring in PD, so that healthy dietary choices might be relevant to reduce the risk of PD (Di Giovanni, 2009; Gao et al., 2007). Therefore, dietary intervention on PD has emerged as a new way to halt disease progression, or even prevent it.
Some studies show that caloric restriction and intermittent fasting diets are neuroprotective and improve functionality in animal models of stroke, Parkinson’s, Huntington’s (Mattson, 2005) and Alzheimer’s (Halagappa et al., 2007) disease. Moreover, data from epidemiological studies suggest that individuals with low-calorie, low-fat diets may have reduced risk of PD (C.C. Johnson et al., 1999; Logroscino et al., 1996), while the potential association between obesity (Abbott et al., 2003; Hu et al., 2006; Ikeda et al., 2007), or cholesterol intake (Miyake et al., 2010) and the risk of PD have been shown. Accordingly, MPTP treatment produces greater striatal dopamine depletion in high-fat-fed than in control mice (J.Y. Choi et al., 2005). Likewise, rats under high-fat diet for 5 weeks before 6-OHDA infusion into the medial forebrain bundle exhibit greater dopamine depletion in the
Caloric restriction and reduced meal frequency/intermittent fasting are dietary manipulations thought to prolong the health span of the nervous system by acting upon important metabolic and cellular signalling pathways to stimulate the production of protein chaperones, antioxidant enzymes, and neurotrophic factors that help cells to deal with stress and resist disease (Martin et al., 2006). The effect of dietary restriction on GDNF levels was not addressed by Duan & Mattson (1999), but an increase in GDNF levels in the nigrostriatal system may play a role in the positive effect of dietary restriction on MPTP-damaged dopaminergic neurons and motor impairment reported by these authors. In fact, more recent observations indicate that a low-calorie diet reduces the loss of dopaminergic neurons from the
Since caloric restriction increases the amount of endogenous GDNF in the brain of monkeys, it may be possible to ameliorate PD, at least partially, through dietary manipulations. It is also worthy to mention that, for instance, hippocampal BDNF levels are reduced in rats subjected to a saturated-fat diet (H.R. Park et al., 2010; D.C. Wu et al., 2003) which leads us to hypothesize that a similar reduction of GDNF levels might also occur under a high-fat diet. Consistent with the observation that caloric restriction attenuates MPTP-induced depletion of dopamine, the distance moved and speed of movement increased more than two-fold in caloric restricted monkeys compared with those on control diet (Maswood et al., 2004). From an evolutionary point of view, and based on experimental data, it was speculated that the neuroprotective effects of caloric restriction could be due to the induction of growth factors by increased motor activity (Finch, 2004). In fact, activation of the same cellular and molecular pathways that occur in response to mild dietary restriction and intermittent fasting-induced stress can occur in response to physical exercise and cognitive stimulation (Mattson et al., 2004).
Taken together, these evidences support the relevance that dietary intervention might assume as a non-invasive and drug-free strategy for PD management, and suggest that an amelioration of GDNF levels may be involved in the protective effects of a healthy diet and caloric restriction on the nigrostriatal pathway.
5.2. Exercising for GDNF expression?
Substantial evidence suggests a positive role of exercise in slowing the progression of PD (Crizzle & Newhouse, 2006; Falvo et al., 2008; Goodwin et al., 2008), and beneficial effects of exercise on motor and non-motor PD symptoms have been described (Gage & Storey, 2004; Lehman et al., 2005; Logroscino et al., 2006). In addition, epidemiological studies show a negative correlation between the regular practice of exercise and the prevalence of PD (H. Chen et al., 2005; Sasco et al., 1992; Tsai et al., 2002; Q. Xu et al., 2010). Interestingly, it has been recently reported that forced exercise is more beneficial for people with PD than voluntary exercise (Ridgel et al., 2009). Thus, exercise might constitute a non-pharmacological neuroprotective therapy for PD contributing to slow the progressive degeneration of dopaminergic neurons. However, there is a lack of consensus on the optimal delivery and extent of exercise (dosing, type, etc) appropriate at each stage of the disease (Dibble et al., 2009; Goodwin et al., 2008). The mechanisms implicated in the beneficial effect of exercise in PD patients are now being uncovered (M.A. Hirsch & Farley, 2009). In particular, several trophic factors might be involved in the beneficial effects of exercise (e.g. Cotman et al., 2007; Gomez-Pinilla et al., 1998; Widenfalk et al., 1999; Yasuhara et al., 2007).
The data from animal models parallel the observations in PD patients as increased physical activity is neuroprotective/neurorestorative in models of nigrostriatal injury. However, despite the findings supporting the view that exercise protects against the behavioral effects of 6-OHDA and MPTP, data on the protection of dopaminergic neurons from 6-OHDA- or MPTP-induced toxicity are mixed (Zigmond et al., 2009). It has been reported that running for 3 months prior to acute MPTP administration completly protects from TH cell loss (Gerecke et al., 2010). On the other hand, exercise for 2 weeks after intrastriatal injection of 6-OHDA results in partial recovery of TH labeling and axonal fiber projection to the striatum (Yoon et al., 2007). Treadmill exercise starting the day after intrastriatal 6-OHDA infusion induces significant preservation of TH-positive fibers in the striatum and TH-positive neurons in the
Physical exercise increases the expression of GDNF in the nigrostriatal system, and this correlates with the protection of dopaminergic neurons against MPTP toxicity (Faherty et al., 2005), and amelioration of motor impairment due to a 6-OHDA lesion (Cohen et al., 2003; Tajiri et al., 2010). Exercise in the running-wheel markedly accelerates spontaneous recovery after a 6-OHDA lesion as animals exercised on the running-wheel prior or after a unilateral striatal 6-OHDA injection show a faster motor recovery compared to non-exercised animals (O'Dell et al., 2007). Recently, daily treadmill exercise similar to clinical settings (30 min/day, 5 days/week for 4 weeks) was shown to up-regulate both GDNF and BDNF in the lesioned and intact sides of the striatum (Tajiri et al., 2010). In a chronic MPTP mouse model with moderate neurodegeneration treadmill exercise during 18 weeks drastically increased GDNF levels in the striatum but not in the
5.3. A stimulating GDNF lifestyle?
Environmental enrichment is characterized by housing conditions that facilitate sensory, motor and cognitive stimuli, accompanied by voluntary physical activity and social interactions. An enriched environment is neuroprotective in animal models of PD. Mice reared in an enriched environment are more resistant to MPTP compared with mice raised in a standard environment (Bezard et al., 2003; Faherty et al., 2005). Moreover, environmental enrichement also improves motor function after unilateral 6-OHDA injection in rats (Jadavji et al., 2006; Steiner et al., 2006). More recently, continuous exposure to environmental enrichement during 3 weeks before and after 6-OHDA injection was reported to prevent dopaminergic neuronal death, protect the nigrostriatal pathway, and reduce motor impairment (Anastasia et al., 2009). The molecular mechanisms involved in the neuroprotective effect of environmental enrichement observed in several rodent models of brain disorders are not clear, but the synthesis and release of neurotrophic factors may play a crucial role (Nithianantharajah & Hannan, 2006). In fact, environmental enrichment increases GDNF mRNA in the
What is the relevance of the results obtained in animal models of PD to humans suffering the disease? Most individuals are exposed to a high degree of environmental complexity and novelty. However, the level of cognitive, social and physical stimulation can vary significantly from one person to another, so that correlative and epidemiological data shows that lifestyle, including occupation, leisure activities and physical exercise, has a direct effect on the risk of cognitive decline (Baroncelli et al., 2010). In fact, there is an association between higher educational accomplishment and reduced risk of PD-related dementia (Glatt et al., 1996). Since PD patients suffer from impaired cognitive functions (Jokinen et al., 2009 and references therein), and GDNF contributes to synaptic transmission (Saavedra et al., 2008). Thus, getting engaged in higher levels of mental and physical activity through education, occupation and recreation might constitute a non-invasive and drug-free approach to increase GDNF levels, which, in turn, might both protect the nigrostriatal pathway and reduce the cognitive impairment affecting PD patients.
5.4. Green GDNF?
Consistent with the considerable effort in identifying naturally occurring neuroprotective substances, growing evidence indicates that many oriental herbs and extracts attenuate the degeneration of dopaminergic neurons, and ameliorate the parkinsonism induced by MPTP and 6-OHDA (for a review see L.W. Chen et al., 2007). The number of reports supporting the neuroprotective action of several herbs and herbal extracts on PD models continues to rise, and here we briefly overview the most recent studies.
Several mechanisms have been proposed to contribute to the neuroprotective effect of herbs and herbal extracts. These include their function as antioxidants to alleviate oxidative stress, inhibitors of monoamine oxidase B to decrease neurotoxicity, scavengers of free radicals, chelators of harmful metals, modulators of cell survival genes and apoptotic signals (L.W. Chen et al., 2007). As a result, herbs and herbal extracts are receiving increasing attention as therapeutic agents for the treatment of PD. The efficacy and safety of their use in adjunct or monotherapy in PD management is under consideration (Chung et al., 2006). Unfortunately, the effect on GDNF expression has not yet been addressed for many of them. It would be very interesting to investigate if these and other herbal extracts are able to increase GDNF expression, as well as whether their protective effects in PD models are mediated, or not, by the up-regulation of GDNF expression. The available data on GDNF induction by herbs or herbal compounds is reviewed below.
Smilagenin is a compound extracted from
Ibogaine is a psychoactive compound extracted from
Given the neuroprotective effect of some herbal extracts on animal and cellular models of PD, and the ability to induce GDNF expression reported for some of them, it may prove useful to screen traditional therapies for their effect on GDNF levels in the nigrostriatal system, as they might reveal to be valuable GDNF inducers and alternative therapeutic approaches to PD.
Acupuncture is among the complementary and/or alternative therapies most widely used by PD patients (Lokk & Nilsson, 2010; Pecci et al., 2010). Interestingly, increasing evidence supports a beneficial effect of acupuncture on MPTP (Y.G. Choi et al., 2011; Doo et al., 2010a; Jeon et al., 2008; J.M. Kang et al., 2007), 6-OHDA (Y.K. Kim et al., 2005; H.J. Park et al., 2003; Y.P. Yu et al., 2010) and medial forebrain bundle transection (Jia et al., 2009, 2010; X.B. Liang et al., 2003) PD models, and also in PD patients (Chang et al., 2008; Zhuang & Wang, 2000). Acupuncture can enhance the therapeutic effects of western medicine and reduce the need of medication (Ren, 2008). Relevant in the context of the present sinopsis is the fact that acupuncture therapy increases various neuroprotective agents (Joh et al., 2010), namely GDNF. In medial forebrain bundle-transected rats, high frequency electroacupunture stimulation up-regulates GDNF mRNA levels in both sides of the globus pallidus, suggesting that the retrograde nourishment of GDNF to dopaminergic neurons may contribute to the behavioral improvement observed in these rats (X.B. Liang et al., 2003). Another study shows that the number of GDNF-positive cells and the content of Ret receptor increased significantly in 6-OHDA-injected rats subjected to electroacupuncture (Y.C. Wang et al., 2010). At this point it is also worthy to mention that acupuncture attenuates microglial activation and inflammatory events in MPTP-treated mice (J.M. Kang et al., 2007). Since acupuncture increases GDNF expression, and GDNF is an important inhibitor of microglia activation (see section 3.3 Role of GDNF in controlling microglia activation), it is tempting to speculate that acupuncture might reduce microglia activity through GDNF up-regulation. Interestingly, electroacupuncture increases GDNF signaling in other disease models. Electroacupuncture activates the endogenous GDNF signaling system by increasing the mRNA and protein levels of GDNF and its receptor GFRα1 in dorsal root ganglions of neuropathic pain rats (Dong et al., 2005). In contrast, electroacupuncture-induced analgesia in a rat model of neuropathic pain is significantly attenuated by the down-regulation of GFRα1 expression with antisense oligodeoxynucleotides (Dong et al., 2006). Electroacupuncture also up-regulates GDNF expression in a model of transient focal cerebral ischemia, thereby extending the duration of the endogenous GDNF up-regulation, which may be one of the pathways involved in the protective effect of electroacupuncture against ischemic injury (Wei et al., 2000b). Since the stimulatory effects of electroacupuncture on GDNF/GFRα1 levels have been demonstrated in different models, it would be relevant to address whether they underlie the beneficial effects of electroacupuncture in PD animals models.
Male gender, together with the sex dimorphism in the nigrostriatal system, can contribute to the gender differences in PD. The estrogen 17β-estradiol plays a determinant protective role through its antioxidant, anti-inflammatory, and anti-apoptotic actions. Moreover, 17β-estradiol is capable of inducing the expression of neurotrophic factors, namely GDNF, which can have a determinant contribution to the aforementioned protective effects of 17β-estradiol. Although the protective effect of 17β-estradiol in females is consensual, the role of this hormone in males is still not broadly accepted.
Microglia plays a protective role by removing apoptotic neurons and by promoting neuronal survival through the release of neurotrophic factors. However, microglia activation can also play a particularly deleterious role in the nigrostriatal system, contributing to further enhance neuronal injury in PD. Substantial evidence suggests that microglial activation is capable of inducing GDNF expression, and more recent data indicate that GDNF in turn inhibits microglia activation. This may indicate that GDNF is involved in a process that self-limits microglial neurotoxicity thus preventing neuronal injury. The extensive neuroinflammation observed in PD brain indicates that this mechanism of control is no longer effective in the diseased brain. Although the results obtained so far with anti-inflammatory drugs were not conclusive, it would be important to determine what causes the disruption or alteration of this feedback mechanism in the course of PD.
The possibility of manipulating endogenous GDNF expression can have clinical implications for the management of PD, and prove to be useful as an alternative or a complement to pharmacological or more invasive approaches. Growing evidence shows the possibility of reducing the risk for age-related neurodegenerative disorders through dietary and behavioral changes inducing neuronal survival and plasticity. Thus, dietary manipulations, physical exercise and cognitive stimulation, which are known to induce GDNF up-regulation, represent novel drug-free and non-invasive approaches that may help preventing the onset of degeneration or, in combination with pharmacological treatments, reduce the severity of the motor symptoms through the modulation of GDNF levels. Moreover, the use of alternative therapies like herbal supplements and acupuncture might also prove to be neuroprotecive via GDNF up-regulation in the nigrostriatal system. Thus, these approaches to increase endogenous GDNF levels deserve further investigation. Likewise, the impact on GDNF levels of other complementary and alternative therapies used by PD patients should also be addressed in the future. Moreover, given its involvement in synaptic plasticity and synaptogenesis, GDNF also plays a role in learning and memory. One may therefore speculate that increasing the endogenous GDNF expression would also contribute to fight the cognitive decline observed in PD patients. Additionally, it would be interesting to examine the effect of caloric restriction, physical exercise, enriched environment, herbal extracts or acupuncture, which increase GDNF expression in the nigrostriatal system and are neuroprotective in PD models, on the levels of MANF and CDNF, two other dopaminotrophic factors.
We would like to thank Esther Perez-Navarro for her comments and suggestions.
Abbott R. D. Ross G. W. White L. R. Sanderson W. T. Burchfiel C. M. Kashon M. Sharp D. S. Masaki K. H. Curb J. D. Petrovitch H. 2003Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu-Asia Aging Study. , 250Suppl 3, III30 III39, 0340-5354
Albeck D. S. Hoffer B. J. Quissell D. Sanders L. A. Zerbe G. Granholm A. C. 1997A non-invasive transport system for GDNF across the blood-brain barrier. , 8 9-10, 2293 2298, 0959-4965
Anastasia A. Torre L. de Erausquin G. A. Masco D. H. 2009Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson’s disease. , 109 3 755 765, 0022-3042
Appel E. Kolman O. Kazimirsky G. Blumberg P. M. Brodie C. 1997Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. , 8 15 3309 3312, 0959-4965
Armentero M. T. Levandis G. Bramanti P. Nappi G. Blandini F. 2008Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson’s disease. , 212 2 548 551, 0014-4886
Aron L. Klein R. 2011Repairing the parkinsonian brain with neurotrophic factors. , 34 2 88 100, 0166-2236
Baldereschi M. Di Carlo A. Rocca W. A. Vanni P. Maggi S. Perissinotto E. Grigoletto F. Amaducci L. Inzitari D. 2000Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. , 55 9 1358 1363, 0028-3878
Baroncelli L. Braschi C. Spolidoro M. Begenisic T. Sale A. Maffei L. 2010Nurturing brain plasticity: impact of environmental enrichment. , 17 7 1092 1103, 1350-9047
Barroso-Chinea P. Cruz-Muros I. Aymerich M. S. Rodriguez-Diaz M. Afonso-Oramas D. Lanciego J. L. Gonzalez-Hernandez T. 2005Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. 21 7 1815 1827, 0095-3816X
Batchelor P. E. Liberatore G. T. Porritt M. J. Donnan G. A. Howells D. W. 2000Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum. , 12 10 3462 3468, 0095-3816X
Batchelor P. E. Liberatore G. T. Wong J. Y. Porritt M. J. Frerichs F. Donnan G. A. Howells D. W. 1999Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. , 19 5 1708 1716, 0270-6474
Batchelor P. E. Porritt M. J. Martinello P. Parish C. L. Liberatore G. T. Donnan G. A. Howells D. W. 2002Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. , 21 3 436 453, 1044-7431
Behl C. Skutella T. Lezoualc’h F. Post A. Widmann M. Newton C. J. Holsboer F. 1997Neuroprotection against oxidative stress by estrogens: structure-activity relationship. , 51 4 535 541, 0002-6895X
Benn S. C. Woolf C. J. 2004Adult neuron survival strategies- slamming on the brakes. , 5 9 686 700, 0147-1003X
Bespalov M. M. Saarma M. 2007GDNF family receptor complexes are emerging drug targets. , 28 2 68 74, 0165-6147
Bezard E. Dovero S. Belin D. Duconger S. Jackson-Lewis V. Przedborski S. Piazza P. V. Gross C. E. Jaber M. 2003Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. , 23 35 10999 11007, 1529-2401
Bi J. Jiang B. Liu J. H. Lei C. Zhang X. L. An L. J. 2008Protective effects of catalpol against H2O2-induced oxidative stress in astrocytes primary cultures. , 442 3 224 227, 0304-3940
Bi J. Jiang B. Hao S. Zhang A. Dong Y. Jiang T. An L. 2009Catalpol attenuates nitric oxide increase via ERK signaling pathways induced by rotenone in mesencephalic neurons. , 54 3-4, 264 270, 0197-0186
Biju K. Zhou Q. Li G. Imam S. Z. Roberts J. L. Morgan W. W. Clark R. A. Li S. 2010Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson’s disease. , 18 8 1536 1544, 1525-0016
Block M. L. Hong J. S. 2005Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. , 76 2 77 98, 0301-0082
Block M. L. Zecca L. Hong J. S. 2007Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. 8 1 57 69, 0147-1003X
Boado R. J. Pardridge W. M. 2009Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. , 37 12 2299 2304, 0090-9556
Boado R. J. Zhang Y. Zhang Y. Wang Y. Pardridge W. M. 2007GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. , 100 2 387 396, 1097-0290
Boger H. A. Granholm A. C. Mc Ginty J. F. Middaugh L. D. 2010A dual-hit animal model for age-related parkinsonism. , 90 2 217 229, 1873-5118
Bourque M. Dluzen D. E. Di Paolo T. 2009Neuroprotective actions of sex steroids in Parkinson’s disease. , 30 2 142 157, 1095-6808
Brann D. W. Dhandapani K. Wakade C. Mahesh V. B. Khan M. M. 2007Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. , 72 5 381 405, 0003-9128X
Burke R. E. Antonelli M. Sulzer D. 1998Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. , 71 2 517 525, 0022-3042
Callier S. Morissette M. Grandbois M. Pelaprat D. Di Paolo T. 2001Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. , 41 2 131 138, 0887-4476
Cantuti-Castelvetri I. Keller Mc Gandy. C. Bouzou B. Asteris G. Clark T. W. Frosch M. P. Standaert D. G. 2007Effects of gender on nigral gene expression and parkinson disease. , 26 3 606 614, 0969-9961
Chang X. H. Zhang L. Z. Li Y. J. 2008[Observation on therapeutic effect of acupuncture combined with medicine on Parkinson disease]. , 28 9 645 647, 0255-2930
Chao C. C. Lee E. H. 1999Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: role of antioxidation. , 38 6 913 916, 0028-3908
Chen H. Zhang S. M. Schwarzschild M. A. Hernan M. A. Ascherio A. 2005Physical activity and the risk of Parkinson disease. , 64 4 664 669, 0152-6632X
Chen L. W. Wang Y. Q. Wei L. C. Shi M. Chan Y. S. 2007Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease. , 6 4 273 281, 1871-5273
Chen P. S. Peng G. S. Li G. Yang S. Wu X. Wang C. C. Wilson B. Lu R. B. Gean P. W. Chuang D. M. Hong J. S. 2006Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. , 11 12 1116 1125, 1359-4184
Cheng H. Fu Y. S. Guo J. W. 2004Ability of GDNF to diminish free radical production leads to protection against kainate-induced excitotoxicity in hippocampus. , 14 1 77 86, 1050-9631
Choi H. S. Park M. S. Kim S. H. Hwang B. Y. Lee C. K. Lee M. K. 2010Neuroprotective effects of herbal ethanol extracts from Gynostemma pentaphyllum in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease. , 15 4 2814 2824, 1420-3049
Choi J. Y. Jang E. H. Park C. S. Kang J. H. 2005Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. , 38 6 806 816, 0891-5849
Choi Y. G. Yeo S. Hong Y. M. Lim S. 2011Neuroprotective changes of striatal degeneration-related gene expression by acupuncture in an MPTP mouse model of parkinsonism: microarray analysis. , 31 3 377 391, 1420-3049
Chung V. Liu L. Bian Z. Zhao Z. Leuk F. W. Kum W. F. Gao J. Li M. 2006Efficacy and safety of herbal medicines for idiopathic Parkinson’s disease: a systematic review. , 21 10 1709 1715, 0885-3185
Clarkson E. D. Zawada W. M. Freed C. R. 1997GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro. , 289 2 207 210, 0030-2766X
Cohen A. D. Tillerson J. L. Smith A. D. Schallert T. Zigmond M. J. 2003Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. , 85 2 299 305, 0022-3042
Cotman C. W. Berchtold N. C. Christie L. A. 2007Exercise builds brain health: key roles of growth factor cascades and inflammation. , 30 9 464 472, 0166-2236
Crizzle A. M. Newhouse I. J. 2006Is physical exercise beneficial for persons with Parkinson’s disease? , 16 5 422 425, 0105-0642X
Currie L. J. Harrison M. B. Trugman J. M. Bennett J. P. Wooten G. F. 2004Postmenopausal estrogen use affects risk for Parkinson disease. , 61 6 886 888, 0003-9942
D’Astous M. Morissette M. Di Paolo T. 2004Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. , 47 8 1180 1188, 0028-3908
De Campos F. Cristovão A. C. Baltazar G. 2010Does GDNF contribute to estrogen-mediated neuroprotection?, 5050.28, FENS Fórum 2010, Amsterdam, The Nederlands. July 2010.
Dehmer T. Lindenau J. Haid S. Dichgans J. Schulz J. B. 2000Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. , 74 5 2213 2216, 0022-3042
Di Giovanni G. 2009A diet for dopaminergic neurons? . Supplementa, 73 317 331, 0303-6995
Diaz N. F. Diaz-Martinez N. E. Camacho-Arroyo I. Velasco I. 2009Estradiol promotes proliferation of dopaminergic precursors resulting in a higher proportion of dopamine neurons derived from mouse embryonic stem cells. , 27 5 493 500, 0187-3474X
Dibble L. E. Addison O. Papa E. 2009The effects of exercise on balance in persons with Parkinson’s disease: a systematic review across the disability spectrum. , 33 1 14 26, 1557-0576
Dietz G. P. Valbuena P. C. Dietz B. Meuer K. Mueller P. Weishaupt J. H. Bahr M. 2006Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson’s disease. , 1082 1 61 66, 0006-8993
Ding Y. M. Jaumotte J. D. Signore A. P. Zigmond M. J. 2004Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. , 89 3 776 787, 0022-3042
Dittrich F. Feng Y. Metzdorf R. Gahr M. 1999Estrogen-inducible, sex-specific expression of brain-derived neurotrophic factor mRNA in a forebrain song control nucleus of the juvenile zebra finch. , 96 14 8241 8246, 0027-8424
Dluzen D. E. 2005Unconventional effects of estrogen uncovered. . 26 10 485 487, 0165-6147
Dluzen D. E. Mc Dermott J. L. Liu B. 1996Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. , 66 2 658 666, 0022-3042
Dong Z. Q. Ma F. Xie H. Wang Y. Q. Wu G. C. 2005Changes of expression of glial cell line-derived neurotrophic factor and its receptor in dorsal root ganglions and spinal dorsal horn during electroacupuncture treatment in neuropathic pain rats. , 376 2 143 148, 0304-3940
Dong Z. Q. Ma F. Xie H. Wang Y. Q. Wu G. C. 2006Down-regulation of GFRalpha-1 expression by antisense oligodeoxynucleotide attenuates electroacupuncture analgesia on heat hyperalgesia in a rat model of neuropathic pain. , 69 1 30 36, 0361-9230
Doo A. R. Kim S. T. Kim S. N. Moon W. Yin C. S. Chae Y. Park H. K. Lee H. Park H. J. 2010aNeuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson’s disease. , 32Suppl 1, No. 88 91, 0161-6412
Doo A. R. Kim S. N. Park J. Y. Cho K. H. Hong J. Eun-Kyung K. Moon S. K. Jung W. S. Lee H. Jung J. H. Park H. J. 2010bNeuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo. , 131 2 433 442, 0378-8741
Double K. L. Reyes S. Werry E. L. Halliday G. M. 2010Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? , 92 3 316 329, 0301-0082
Duan W. Mattson M. P. 1999Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson’s disease. , 57 2 195 206, 0360-4012
Duarte E. P. Saavedra A. Baltazar G. 2007GDNF: a key player in neuron-glia crosstalk and survival of nigrostriatal dopaminergic neurons, In: , Malva J. O., Rego A. C., Cunha R. & Oliveira C. R., 173 192, Springer-Verlag, 978-0-38770-830-0Berlin
Evans J. R. Barker R. A. 2008Neurotrophic factors as a therapeutic target for Parkinson’s disease. , 12 4 437 447, 1472-8222
Faherty C. J. Raviie S. K. Herasimtschuk A. Smeyne R. J. 2005Environmental enrichment in adulthood eliminates neuronal death in experimental parkinsonism. Molecular Brain Research, 134 1 170 179, 0016-9328X
Falvo M. J. Schilling B. K. Earhart G. M. 2008Parkinson’s disease and resistive exercise: rationale, review, and recommendations. , 23 1 1 11, 0885-3185
Finch C. E. 2004The neurotoxicology of hard foraging and fat-melts. , 101 52 17887 17888, 0027-8424
Fisher B. E. Petzinger G. M. Nixon K. Hogg E. Bremmer S. Meshul C. K. Jakowec M. W. 2004Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. , 77 3 378 390, 0360-4012
Frank L. Ventimiglia R. Anderson K. Lindsay R. M. Rudge J. S. 1996BDNF down-regulates neurotrophin responsiveness, TrkB protein and TrkB mRNA levels in cultured rat hippocampal neurons. , 8 6 1220 1230, 0095-3816X
Gage H. Storey L. 2004Rehabilitation for Parkinson’s disease: a systematic review of available evidence. Clinical rehabilitation., 18 5 463 482, 0269-2155
Gao X. Chen H. Fung T. T. Logroscino G. Schwarzschild M. A. Hu F. B. Ascherio A. 2007Prospective study of dietary pattern and risk of Parkinson disease. , 86 5 1486 1494, 0002-9165
Garcia-Segura L. M. Cardona-Gomez P. Naftolin F. Chowen J. A. 1998Estradiol upregulates Bcl-2 expression in adult brain neurons. , 9 4 593 597, 0959-4965
Garcia-Segura L. M. Diz-Chaves Y. Perez-Martin M. Darnaudery M. 2007Estradiol, insulin-like growth factor-I and brain aging. , 32Suppl 1, S57 S61, 0306-4530
Georgievska B. Kirik D. Bjorklund A. 2002Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. , 177 2 461 474, 0014-4886
Georgievska B. Kirik D. Bjorklund A. 2004Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. , 24 29 6437 6445, 0270-6474
Gerecke K. M. Jiao Y. Pani A. Pagala V. Smeyne R. J. 2010Exercise protects against MPTP-induced neurotoxicity in mice. , 1341 72 83, 0006-8993
Gill S. S. Patel N. K. Hotton G. R. O’Sullivan K. Mc Carter R. Bunnage M. Brooks D. J. Svendsen C. N. Heywood P. 2003Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. , 9 5 589 595, 1078-8956
Gillies G. E. Mc Arthur S. 2010aIndependent influences of sex steroids of systemic and central origin in a rat model of Parkinson’s disease: A contribution to sex-specific neuroprotection by estrogens. , 57 1 23 34, 1095-6867
Gillies G. E. Mc Arthur S. 2010bEstrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. , 62 2 155 198, 1521-0081
Glatt S. L. Hubble J. P. Lyons K. Paolo A. Troster A. I. Hassanein R. E. Koller W. C. 1996Risk factors for dementia in Parkinson’s disease: effect of education. , 15 1 20 25, 0251-5350
Gomez-Pinilla F. So V. Kesslak J. P. 1998Spatial learning and physical activity contribute to the induction of fibroblast growth factor: neural substrates for increased cognition associated with exercise. , 85 1 53 61, 0306-4522
Goodwin V. A. Richards S. H. Taylor R. S. Taylor A. H. Campbell J. L. 2008The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. , 23 5 631 640, 0885-3185
Haapasalo A. Sipola I. Larsson K. Akerman K. E. Stoilov P. Stamm S. Wong G. Castren E. 2002Regulation of TRKB surface expression by brain-derived neurotrophic factor and truncated TRKB isoforms. , 277 45 43160 43167, 0021-9258
Halagappa V. K. Guo Z. Pearson M. Matsuoka Y. Cutler R. G. Laferla F. M. Mattson M. P. 2007Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer’s disease. , 26 1 212 220, 0969-9961
Halliday G. M. Stevens C. H. 2011Glia: Initiators and progressors of pathology in Parkinson’s disease. , 26 1 6 17, 1531-8257
Hashimoto M. Nitta A. Fukumitsu H. Nomoto H. Shen L. Furukawa S. 2005Inflammation-induced GDNF improves locomotor function after spinal cord injury. , 16 2 99 102, 0959-4965
He D. Y. Ron D. 2006Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. , 20 13 2420 2422, 1530-6860
He D. Y. Mc Gough N. N. Ravindranathan A. Jeanblanc J. Logrip M. L. Phamluong K. Janak P. H. Ron D. 2005Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. , 25 3 619 628, 1529-2401
He Y. Appel S. Le W. 2001Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. , 909 1-2, 187 193, 0006-8993
Hirsch E. C. Hunot S. 2009Neuroinflammation in Parkinson’s disease: a target for neuroprotection? , 8 4 382 397, 1474-4422
Hirsch M. A. Farley B. G. 2009Exercise and neuroplasticity in persons living with Parkinson’s disease. , 45 2 215 229, 1973-9087
Ho A. Blum M. 1998Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. , 18 15 5614 5629, 0270-6474
Hong M. Mukhida K. Mendez I. 2008GDNF therapy for Parkinson’s disease. , 8 7 1125 1139, 1744-8360
Hovland D. N. Boyd R. B. Butt M. T. Engelhardt J. A. Moxness M. S. Ma M. H. Emery M. G. Ernst N. B. Reed R. P. Zeller J. R. Gash D. M. Masterman D. M. Potter B. M. Cosenza M. E. Lightfoot R. M. 2007Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. , 35 7 1013 1029, 0192-6233
Hu G. Jousilahti P. Nissinen A. Antikainen R. Kivipelto M. Tuomilehto J. 2006Body mass index and the risk of Parkinson disease. , 67 11 1955 1959, 0028-3878
Ibanez C. F. 2010Beyond the cell surface: new mechanisms of receptor function. , 396 1 24 27, 1090-2104
Ichikawa H. Sato T. Kano M. Suzuki T. Matsuo S. Kanetaka H. Shimizu Y. 2011Masseteric nerve injury increases expression of Brain-Derived Neurotrophic Factor in microglia within the rat mesencephalic trigeminal tract nucleus. , 31 4 551 559, 1573-6830
Ikeda K. Kashihara H. Tamura M. Kano O. Iwamoto K. Iwasaki Y. 2007Body mass index and the risk of Parkinson disease. , 68 24 2156 2157, 0028-3878
Ivanova T. Karolczak M. Beyer C. 2002Estradiol stimulates GDNF expression in developing hypothalamic neurons. , 143 8 3175 3178, 0013-7227
Ivanova T. Kuppers E. Engele J. Beyer C. 2001Estrogen stimulates brain-derived neurotrophic factor expression in embryonic mouse midbrain neurons through a membrane-mediated and calcium-dependent mechanism. , 66 2 221 230, 0360-4012
Jadavji N. M. Kolb B. Metz G. A. 2006Enriched environment improves motor function in intact and unilateral dopamine-depleted rats. , 140 4 1127 1138, 0306-4522
Jenner P. 2003Oxidative stress in Parkinson’s disease. , 53Suppl 3, 26 36, 0364-5134
Jeon S. Kim Y. J. Kim S. T. Moon W. Chae Y. Kang M. Chung M. Y. Lee H. Hong M. S. Chung J. H. Joh T. H. Lee H. Park H. J. 2008Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson’s disease mouse model. , 8 22 4822 4832, 1615-9853
Jia J. Li B. Sun Z. L. Yu F. Wang X. Wang X. M. 2010Electro-acupuncture stimulation acts on the basal ganglia output pathway to ameliorate motor impairment in Parkinsonian model rats. , 124 2 305 310, 0735-7044
Jia J. Sun Z. Li B. Pan Y. Wang H. Wang X. Yu F. Liu L. Zhang L. Wang X. 2009Electro-acupuncture stimulation improves motor disorders in Parkinsonian rats. , 205 1 214 218, 0166-4328
Joh T. H. Park H. J. Kim S. N. Lee H. 2010Recent development of acupuncture on Parkinson’s disease. , 32Suppl 1, 5 9, 0161-6412
Johnson C. C. Gorell J. M. Rybicki B. A. Sanders K. Peterson E. L. 1999Adult nutrient intake as a risk factor for Parkinson’s disease. , 28 6 1102 1109, 0300-5771
Johnson M. L. Day A. E. Ho C. C. Walker Q. D. Francis R. Kuhn C. M. 2010Androgen decreases dopamine neurone survival in rat midbrain. , 22 4 238 247, 1365-2826
Jokinen P. Bruck A. Aalto S. Forsback S. Parkkola R. Rinne J. O. 2009Impaired cognitive performance in Parkinson’s disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. , 15 2 88 93, 1353-8020
Jourdain S. Morissette M. Morin N. Di Paolo T. 2005Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. , 17 8 509 517, 0953-8194
Kang J. Qian P. X. Pandey V. Perry J. K. Miller L. D. Liu E. T. Zhu T. Liu D. X. Lobie P. E. 2010Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. , 29 22 3228 3240, 1476-5594
Kang J. M. Park H. J. Choi Y. G. Choe I. H. Park J. H. Kim Y. S. Lim S. 2007Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. , 1131 1 211 219, 0006-8993
Kastin A. J. Akerstrom V. Pan W. 2003Glial cell line-derived neurotrophic factor does not enter normal mouse brain. , 340 3 239 241, 0304-3940
Khan M. M. Hoda M. N. Ishrat T. Ahmad A. Khan M. B. Khuwaja G. Raza S. S. Safhi M. M. Islam F. 2010Amelioration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced behavioural dysfunction and oxidative stress by Pycnogenol in mouse model of Parkinson’s disease. , 21 5-6, 563 571, 0955-8810
Kim I. S. Koppula S. Park P. J. Kim E. H. Kim C. G. Choi W. S. Lee K. H. Choi D. K. 2009Chrysanthemum morifolium Ramat (CM) extract protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. , 126 3 447 454, 0378-8741
Kim J. S. Kim J. M. Jj O. Jeon B. S. 2010Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. , 17 9 1165 1168, 0967-5868
Kim Y. K. Lim H. H. Song Y. K. Lee H. H. Lim S. Han S. M. Kim C. J. 2005Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats. , 384 1-2, 133 138, 0304-3940
Kim Y. S. Joh T. H. 2006Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. , 38 4 333 347, 1226-3613
Kipp M. Karakaya S. Pawlak J. Araujo-Wright G. Arnold S. Beyer C. 2006Estrogen and the development and protection of nigrostriatal dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factors. , 27 4 376 390, 0091-3022
Kirik D. Georgievska B. Bjorklund A. 2004Localized striatal delivery of GDNF as a treatment for Parkinson disease. , 7 2 105 110, 1097-6256
Kitamura Y. Inden M. Minamino H. Abe M. Takata K. Taniguchi T. 2010The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra. , 58 14 1686 1700, 1098-1136
Knusel B. Gao H. Okazaki T. Yoshida T. Mori N. Hefti F. Kaplan D. R. 1997Ligand-induced down-regulation of Trk messenger RNA, protein and tyrosine phosphorylation in rat cortical neurons. , 78 3 851 862, 0306-4522
Kuno R. Yoshida Y. Nitta A. Nabeshima T. Wang J. Sonobe Y. Kawanokuchi J. Takeuchi H. Mizuno T. Suzumura A. 2006The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. , 1116 1 12 18, 0006-8993
Kurtzke J. F. Goldberg I. D. 1988Parkinsonism death rates by race, sex, and geography. , 38 10 1558 1561, 0028-3878
Laakso A. Vilkman H. Bergman J. Haaparanta M. Solin O. Syvalahti E. Salokangas R. K. Hietala J. 2002Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. , 52 7 759 763, 0006-3223
Lang A. E. Gill S. Patel N. K. Lozano A. Nutt J. G. Penn R. Brooks D. J. Hotton G. Moro E. Heywood P. Brodsky M. A. Burchiel K. Kelly P. Dalvi A. Scott B. Stacy M. Turner D. Wooten V. G. Elias W. J. Laws E. R. Dhawan V. Stoessl A. J. Matcham J. Coffey R. J. Traub M. 2006Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. , 59 3 459 466, 0364-5134
Larsen K. E. Benn S. C. Ay I. Chian R. J. Celia S. A. Remington M. P. Bejarano M. Liu M. Ross J. Carmillo P. Sah D. Phillips K. A. Sulzer D. Pepinsky R. B. Fishman P. S. Brown R. H. Francis J. W. 2006A glial cell line-derived neurotrophic factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice. , 1120 1 1 12, 0006-8993
Lau Y. S. Patki G. Das-Panja K. Le W. D. Ahmad S. O. 2011Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson’s disease with moderate neurodegeneration. , 33 7 1264 1274, 0095-3816X
Lauterborn J. C. Pineda E. Chen L. Y. Ramirez E. A. Lynch G. Gall C. M. 2009Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression. , 159 1 283 295, 0306-4522
Lee C. H. Hwang D. S. Kim H. G. Oh H. Park H. Cho J. H. Lee J. M. Jang J. B. Lee K. S. Oh M. S. 2010Protective effect of Cyperi rhizoma against 6-hydroxydopamine-induced neuronal damage. , 13 3 564 571, 0109-6620X
Lehman D. A. Toole T. Lofald D. Hirsch M. A. 2005Training with verbal instructional cues results in near-term improvement of gait in people with Parkinson disease. , 29 1 2 8, 1557-0576
Liang J. Takeuchi H. Jin S. Noda M. Li H. Doi Y. Kawanokuchi J. Sonobe Y. Mizuno T. Suzumura A. 2010Glutamate induces neurotrophic factor production from microglia via protein kinase C pathway. , 1322 8 23, 1872-6240
Liang X. B. Luo Y. Liu X. Y. Lu J. Li F. Q. Wang Q. Wang X. M. Han J. S. 2003Electro-acupuncture improves behavior and upregulates GDNF mRNA in MFB transected rats. , 14 8 1177 1181, 0959-4965
Liberatore G. T. Wong J. Y. Porritt M. J. Donnan G. A. Howells D. W. 1997Expression of glial cell line-derived neurotrophic factor (GDNF) mRNA following mechanical injury to mouse striatum. , 8 14 3097 3101, 0959-4965
Liberatore G. T. Jackson-Lewis V. Vukosavic S. Mandir A. S. Vila M. Mc Auliffe W. G. Dawson V. L. Dawson T. M. Przedborski S. 1999Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. , 5 12 1403 1409, 1078-8956
Lin L. F. Doherty D. H. Lile J. D. Bektesh S. Collins F. 1993 GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 260 5111 1130 1132, 0036-8075
Lindholm P. Voutilainen M. H. Lauren J. Peranen J. Leppanen V. M. Andressoo J. O. Lindahl M. Janhunen S. Kalkkinen N. Timmusk T. Tuominen R. K. Saarma M. 2007Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. , 448 7149 73 77, 1476-4687
Liu B. Dluzen D. E. 2007Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson’s disease. , 34 7 555 565, 0305-1870
Liu X. Fan X. L. Zhao Y. Luo G. R. Li X. P. Li R. Le W. D. 2005Estrogen provides neuroprotection against activated microglia-induced dopaminergic neuronal injury through both estrogen receptor-alpha and estrogen receptor-beta in microglia. , 81 5 653 665, 0360-4012
Logroscino G. Sesso H. D. Paffenbarger R. S. Lee I. M. 2006Physical activity and risk of Parkinson’s disease: a prospective cohort study. , 77 12 1318 1322, 0146-8330X
Logroscino G. Marder K. Cote L. Tang M. X. Shea S. Mayeux R. 1996Dietary lipids and antioxidants in Parkinson’s disease: a population-based, case-control study. , 39 1 89 94, 0364-5134
Lokk J. Nilsson M. 2010Frequency, type and factors associated with the use of complementary and alternative medicine in patients with Parkinson’s disease at a neurological outpatient clinic. , 16 8 540 544, 1353-8020
Love S. Plaha P. Patel N. K. Hotton G. R. Brooks D. J. Gill S. S. 2005Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. , 11 7 703 704, 1078-8956
Luo F. C. Wang S. D. Qi L. Song J. Y. Lv T. Bai J. 2011Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo. , 133 2 448 453, 0378-8741
Lynch M. A. 2009The multifaceted profile of activated microglia. , 40 2 139 156, 0893-7648
Mabandla M. Kellaway L. St Clair. G. A. Russell V. A. 2004Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle. , 19 1-2, 43 50, 0885-7490
Madinier A. Bertrand N. Mossiat C. Prigent-Tessier A. Beley A. Marie C. Garnier P. 2009Microglial involvement in neuroplastic changes following focal brain ischemia in rats. , 4 12 e8101 1932-6203
Manfredsson F. P. Okun M. S. Mandel R. J. 2009Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson’s disease. , 9 5 375 388, 1566-5232
Marder K. Tang M. X. Mejia H. Alfaro B. Cote L. Louis E. Groves J. Mayeux R. 1996Risk of Parkinson’s disease among first-degree relatives: A community-based study. , 47 1 155 160, 0028-3878
Marks W. J. Ostrem J. L. Verhagen L. Starr P. A. Larson P. S. Bakay R. A. Taylor R. Cahn-Weiner D. A. Stoessl A. J. Olanow C. W. Bartus R. T. 2008Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. , 7 5 400 408, 1474-4422
Marks W. J. Bartus R. T. Siffert J. Davis C. S. Lozano A. Boulis N. Vitek J. Stacy M. Turner D. Verhagen L. Bakay R. Watts R. Guthrie B. Jankovic J. Simpson R. Tagliati M. Alterman R. Stern M. Baltuch G. Starr P. A. Larson P. S. Ostrem J. L. Nutt J. Kieburtz K. Kordower J. H. Olanow C. W. 2010Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. , 9 12 1164 1172, 1474-4422
Martin B. Mattson M. P. Maudsley S. 2006Caloric restriction and intermittent fasting: two potential diets for successful brain aging. , 5 3 332 353, 1568-1637
Maswood N. Young J. Tilmont E. Zhang Z. Gash D. M. Gerhardt G. A. Grondin R. Roth G. S. Mattison J. Lane M. A. Carson R. E. Cohen R. M. Mouton P. R. Quigley C. Mattson M. P. Ingram D. K. 2004Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson’s disease. , 101 52 18171 18176, 0027-8424
Mattson M. P. 2005Energy intake, meal frequency, and health: a neurobiological perspective. , 25No. 237 260, 0199-9885
Mattson M. P. Magnus T. 2006Ageing and neuronal vulnerability. , 7 4 278 294, 0147-1003X
Mattson M. P. Duan W. Wan R. Guo Z. 2004Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. , 1 1 111 116, 1545-5343
Mayeux R. Denaro J. Hemenegildo N. Marder K. Tang M. X. Cote L. J. Stern Y. 1992A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. , 49 5 492 497, 0003-9942
Mc Naught K. S. Jenner P. 2000Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release. , 285 1 61 65, 0304-3940
Miller I. N. Cronin-Golomb A. 2010Gender differences in Parkinson’s disease: clinical characteristics and cognition. , 25 16 2695 2703, 1531-8257
Min K. J. Yang M. S. Kim S. U. Jou I. Joe E. H. 2006Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. , 26 6 1880 1887, 1529-2401
Miyake Y. Sasaki S. Tanaka K. Fukushima W. Kiyohara C. Tsuboi Y. Yamada T. Oeda T. Miki T. Kawamura N. Sakae N. Fukuyama H. Hirota Y. Nagai M. 2010Dietary fat intake and risk of Parkinson’s disease: a case-control study in Japan. , 288 1-2, 117 122, 0002-2510X
Mochizuki H. Goto K. Mori H. Mizuno Y. 1996Histochemical detection of apoptosis in Parkinson’s disease. , 137 2 120 123, 0002-2510X
Mooradian A. D. 1993Antioxidant properties of steroids. , 45 6 509 511, 0960-0760
Morale M. C. Serra P. A. L’Episcopo F. Tirolo C. Caniglia S. Testa N. Gennuso F. Giaquinta G. Rocchitta G. Desole M. S. Miele E. Marchetti B. 2006Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: glia dictates resistance versus vulnerability to neurodegeneration. , 138 3 869 878, 0306-4522
Morissette M. Le Saux M. D’Astous M. Jourdain S. Al Sweidi. S. Morin N. Estrada-Camarena E. Mendez P. Garcia-Segura L. M. Di Paolo T. 2008Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. , 108 3-5, 327 338, 0960-0760
Morris J. K. Bomhoff G. L. Stanford J. A. Geiger P. C. 2010Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet. , 299 4 R1082 R1090, 0363-6119
Munro C. A. Mc Caul M. E. Wong D. F. Oswald L. M. Zhou Y. Brasic J. Kuwabara H. Kumar A. Alexander M. Ye W. Wand G. S. 2006Sex differences in striatal dopamine release in healthy adults. , 59 10 966 974, 0006-3223
Murray H. E. Pillai A. V. Mc Arthur S. R. Razvi N. Datla K. P. Dexter D. T. Gillies G. E. 2003Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. , 116 1 213 222, 0306-4522
Nithianantharajah J. Hannan A. J. 2006Enriched environments, experience-dependent plasticity and disorders of the nervous system. , 7 9 697 709, 0147-1003X
Nitta A. Nishioka H. Fukumitsu H. Furukawa Y. Sugiura H. Shen L. Furukawa S. 2004Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis. , 78 2 250 258, 0360-4012
Nutt J. G. Burchiel K. J. Comella C. L. Jankovic J. Lang A. E. Laws E. R. Lozano A. M. Penn R. D. Simpson R. K. Stacy M. Wooten G. F. 2003Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. , 60 1 69 73, 0028-3878
O’Dell S. J. Gross N. B. Fricks A. N. Casiano B. D. Nguyen T. B. Marshall J. F. 2007Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection. , 144 3 1141 1151, 0306-4522
Pan M. Li Z. Yeung V. Xu R. J. 2010Dietary supplementation of soy germ phytoestrogens or estradiol improves spatial memory performance and increases gene expression of BDNF, TrkB receptor and synaptic factors in ovariectomized rats. , 7 75 1743-7075
Parish C. L. Finkelstein D. I. Tripanichkul W. Satoskar A. R. Drago J. Horne M. K. 2002The role of interleukin-1, interleukin-6, and glia in inducing growth of neuronal terminal arbors in mice. , 22 18 8034 8041, 1529-2401
Park H. J. Lim S. Joo W. S. Yin C. S. Lee H. S. Lee H. J. Seo J. C. Leem K. Son Y. S. Kim Y. J. Kim C. J. Kim Y. S. Chung J. H. 2003Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson’s disease model. , 180 1 93 98, 0014-4886
Park H. R. Park M. Choi J. Park K. Y. Chung H. Y. Lee J. 2010A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. , 482 3 235 239, 0304-3940
Pascual A. Hidalgo-Figueroa M. Piruat J. I. Pintado C. O. Gomez-Diaz R. Lopez-Barneo J. 2008Absolute requirement of GDNF for adult catecholaminergic neuron survival. , 11 7 755 761, 1097-6256
Pecci C. Rivas M. J. Moretti C. M. Raina G. Ramirez C. Z. Diaz S. Uribe R. C. Micheli F. E. 2010Use of complementary and alternative therapies in outpatients with Parkinson’s disease in Argentina. , 25 13 2094 2098, 0885-3185
Peng G. S. Li G. Tzeng N. S. Chen P. S. Chuang D. M. Hsu Y. D. Yang S. Hong J. S. 2005Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. , 134 1 162 169, 0016-9328X
Peterson A. L. Nutt J. G. 2008Treatment of Parkinson’s disease with trophic factors. , 5 2 270 280, 1878-7479
Petrova P. Raibekas A. Pevsner J. Vigo N. Anafi M. Moore M. K. Peaire A. E. Shridhar V. Smith D. I. Kelly J. Durocher Y. Commissiong J. W. 2003MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. , 20 2 173 188, 0895-8696
Petzinger G. M. Walsh J. P. Akopian G. Hogg E. Abernathy A. Arevalo P. Turnquist P. Vucković M. Fisher B. E. Togasaki D. M. Jakowec M. W. 2007Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. , 27 20 5291 5300. 1529-2401
Pietranera L. Lima A. Roig P. De Nicola A. F. 2010Involvement of brain-derived neurotrophic factor and neurogenesis in oestradiol neuroprotection of the hippocampus of hypertensive rats. , 22 10 1082 1092, 1365-2826
Platania P. Seminara G. Aronica E. Troost D. Vincenza Catania. M. Angela Sortino. M. 200517beta-estradiol rescues spinal motoneurons from AMPA-induced toxicity: a role for glial cells. , 20 2 461 470, 0969-9961
Przedborski S. Ischiropoulos H. 2005Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson’s disease. , 7 5-6, 685 693, 1523-0864
Rajasankar S. Manivasagam T. Surendran S. 2009aAshwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson’s disease. , 454 1 11 15, 0304-3940
Rajasankar S. Manivasagam T. Sankar V. Prakash S. Muthusamy R. Krishnamurti A. Surendran S. 2009bWithania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. , 125 3 369 373, 0378-8741
Ramaswamy S. Soderstrom K. E. Kordower J. H. 2009Trophic factors therapy in Parkinson’s disease. , 175No. 201 216, 0079-6123
Ramirez A. D. Liu X. Menniti F. S. 2003Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. , 77 4 223 231, 0028-3835
Ratan R. R. Murphy T. H. Baraban J. M. 1994Oxidative stress induces apoptosis in embryonic cortical neurons. , 62 1 376 379, 0022-3042
Remy S. Naveilhan P. Paille V. Brachet P. Neveu I. 2003Lipopolysaccharide and TNFalpha regulate the expression of GDNF, neurturin and their receptors. , 14 11 1529 1534, 0022-3042
Ren X. M. 2008Fifty cases of Parkinson’s disease treated by acupuncture combined with madopar. , 28 4 255 257, 0255-2922
Ridgel A. L. Vitek J. L. Alberts J. L. 2009Forced, not voluntary, exercise improves motor function in Parkinson’s disease patients. , 23 6 600 608, 1552-6844
Rocha S. C. M. Cristovão A. C. Branco D. Baltazar G. 2010Astrocyte-derived GDNF is able to prevent the activation of midbrain microglia induced by Zymosan A. 5164.33, FENS Fórum 2010, Amsterdam. The Nederlands. July 2010.
Rodriguez-Navarro J. A. Solano R. M. Casarejos M. J. Gomez A. Perucho J. de Yebenes J. G. Mena M. A. 2008Gender differences and estrogen effects in parkin null mice. , 106 5 2143 2157, 1471-4159
Ron D. Janak P. H. 2005GDNF and addiction. , 16 4 277 285, 1651-9005
Rosenblad C. Georgievska B. Kirik D. 2003Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. , 17 2 260 270, 0095-3816X
Saavedra A. Baltazar G. Duarte E. P. 2007Interleukin-1beta mediates GDNF up-regulation upon dopaminergic injury in ventral midbrain cell cultures. , 25 1 92 104, 0969-9961
Saavedra A. Baltazar G. Duarte E. P. 2008Driving GDNF expression: the green and the red traffic lights. , 86 3 186 215, 0301-0082
Saavedra A. Baltazar G. Carvalho C. M. Duarte E. P. 2005GDNF modulates HO-1 expression in substantia nigra postnatal cell cultures. , 39 12 1611 1619, 0891-5849
Saavedra A. Baltazar G. Santos P. Carvalho C. M. Duarte E. P. 2006 Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. , 23 3 533 542, 0969-9961
Sapkota K. Kim S. Kim M. K. Kim S. J. 2010A detoxified extract of Rhus verniciflua Stokes upregulated the expression of BDNF and GDNF in the rat brain and the human dopaminergic cell line SH-SY5Y. , 74 10 1997 2004, 0916-8451
Sapkota K. Kim S. Park S. E. Kim S. J. 2011Detoxified extract of Rhus verniciflua Stokes inhibits rotenone-induced apoptosis in human dopaminergic cells, SH-SY5Y. , 31 2 213 223, 0272-4340
Sasco A. J. Paffenbarger R. S. Gendre I. Wing A. L. 1992The role of physical exercise in the occurrence of Parkinson’s disease. , 49 4 360 365, 0003-9942
Satake K. Matsuyama Y. Kamiya M. Kawakami H. Iwata H. Adachi K. Kiuchi K. 2000Up-regulation of glial cell line-derived neurotrophic factor (GDNF) following traumatic spinal cord injury. , 11 17 3877 3881, 0959-4965
Sawada H. Ibi M. Kihara T. Urushitani M. Akaike A. Shimohama S. 1998Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. Research, 54 5 707 719, 0306-4012
Sawada H. Ibi M. Kihara T. Urushitani M. Honda K. Nakanishi M. Akaike A. Shimohama S. 2000Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. , 14 9 1202 1214, 0892-6638
Schreiber S. L. 1991Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 251 4991 283 287, 0036-8075
Sherer T. B. Fiske B. K. Svendsen C. N. Lang A. E. Langston J. W. 2006Crossroads in GDNF therapy for Parkinson’s disease. , 21 2 136 141, 0885-3185
Shulman L. M. 2007Gender differences in Parkinson’s disease. , 4 1 8 18, 1550-8579
Siegel G. J. Chauhan N. B. 2000Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain. , 33 2-3, 199 227, 0165-0173
Singer C. A. Rogers K. L. Dorsa D. M. 1998Modulation of Bcl-2 expression: a potential component of estrogen protection in NT2 neurons. , 9 11 2565 2568, 0959-4965
Slevin J. T. Gerhardt G. A. Smith C. D. Gash D. M. Kryscio R. Young B. 2005Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 102 2 216 222, 0022-3085
Smith A. D. Zigmond M. J. 2003Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. , 184 1 31 39, 0014-4886
Smith B. A. Goldberg N. R. S. Meshul C. K. 2011Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse. , 1386 70 80, 0006-8993
Smith M. P. Cass W. A. 2007GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson’s disease. , 412 3 259 263, 0304-3940
Soderstrom K. O’Malley J. Steece-Collier K. Kordower J. H. 2006Neural repair strategies for Parkinson’s disease: insights from primate models. , 15 3 251 265, 0963-6897
Sriram K. Benkovic S. A. Miller D. B. O’Callaghan J. P. 2002Obesity exacerbates chemically induced neurodegeneration. , 115 4 1335 1346, 0306-4522
Steiner B. Winter C. Hosman K. Siebert E. Kempermann G. Petrus D. S. Kupsch A. 2006Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson’s disease. , 199 2 291 300, 0014-4886
Sutoo D. Akiyama K. 2003Regulation of brain function by exercise. , 13 1 1 14, 0969-9961
Tajiri N. Yasuhara T. Shingo T. Kondo A. Yuan W. Kadota T. Wang F. Baba T. Tayra J. T. Morimoto T. Jing M. Kikuchi Y. Kuramoto S. Agari T. Miyoshi Y. Fujino H. Obata F. Takeda I. Furuta T. Date I. 2010Exercise exerts neuroprotective effects on Parkinson’s disease model of rats. , 1310 200 207, 0006-8993
Tan S. Wood M. Maher P. 1998Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. , 71 1 95 105, 0022-3042
Tansey M. G. Goldberg M. S. 2010Neuroinflammation in Parkinson’s disease: Its role in neuronal death and implications for therapeutic intervention. , 37 3 510 518, 0109-5953X
Tatarewicz S. M. Wei X. Gupta S. Masterman D. Swanson S. J. Moxness M. S. 2007Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson’s disease receiving r-metHuGDNF via continuous intraputaminal infusion. , 27 6 620 627, 0271-9142
Tian Y. Y. Jiang B. An L. J. Bao Y. M. 2007Neuroprotective effect of catalpol against MPP(+)-induced oxidative stress in mesencephalic neurons. , 568 1-3, 142 148, 0014-2999
Tillerson J. L. Caudle W. M. Reveron M. E. Miller G. W. 2003Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson’s disease. , 119 3 899 911, 0306-4522
Tillerson J. L. Cohen A. D. Philhower J. Miller G. W. Zigmond M. J. Schallert T. 2001Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. , 21 12 4427 4435, 1529-2401
Tokugawa K. Yamamoto K. Nishiguchi M. Sekine T. Sakai M. Ueki T. Chaki S. Okuyama S. 2003XIB4035, a novel nonpeptidyl small molecule agonist for GFRalpha-1. , 42 1 81 86, 0197-0186
Tripanichkul W. Sripanichkulchai K. Finkelstein D. I. 2006Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication. , 1084 1 28 37, 0006-8993
Tsai C. H. Lo S. K. See L. C. Chen H. Z. Chen R. S. Weng Y. H. Chang F. C. Lu C. S. 2002Environmental risk factors of young onset Parkinson’s disease: a case-control study. , 104 4 328 333, 0303-8467
Turner C. A. Lewis M. H. 2003Environmental enrichment: effects on stereotyped behavior and neurotrophin levels. , 80 2-3, 259 266, 0031-9384
Vastag B. 2010Biotechnology: Crossing the barrier. , 466 7309 916 918, 0028-0836
Vegeto E. Pollio G. Pellicciari C. Maggi A. 1999Estrogen and progesterone induction of survival of monoblastoid cells undergoing TNF-alpha-induced apoptosis. , 13 8 793 803, 0892-6638
Vegeto E. Bonincontro C. Pollio G. Sala A. Viappiani S. Nardi F. Brusadelli A. Viviani B. Ciana P. Maggi A. 2001Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. , 21 6 1809 1818, 1529-2401
Verity A. N. Wyatt T. L. Hajos B. Eglen R. M. Baecker P. A. Johnson R. M. 1998Regulation of glial cell line-derived neurotrophic factor release from rat C6 glioblastoma cells. , 70 2 531 539, 0042-3042
Verity A. N. Wyatt T. L. Lee W. Hajos B. Baecker P. A. Eglen R. M. Johnson R. M. 1999Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. , 55 2 187 197, 0360-4012
Visanji N. P. Orsi A. Johnston T. H. Howson P. A. Dixon K. Callizot N. Brotchie J. M. Rees D. D. 2008PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson’s disease. , 22 7 2488 2497, 1530-6860
Wang X. J. Ye M. Zhang Y. H. Chen S. D. 2007CD200-CD200R regulation of microglia activation in the pathogenesis of Parkinson’s disease. , 2 3 259 264, 1557-1904
Wang Y. C. Cheng Y. H. Ma J. Gan S. Y. Wang S. J. Zhou H. Du Y. J. Yang M. Shen F. 2010[Effects of electroacupuncture on the expression of GDNF and Ret in Parkinson’s disease model rats]. , 30 9 739 743, 0255-2930
Wei G. Wu G. Cao X. 2000aDynamic expression of glial cell line-derived neurotrophic factor after cerebral ischemia. , 11 6 1177 1183, 0959-4969
Wei G. Huang Y. Wu G. Cao X. 2000bRegulation of glial cell line-derived neurotrophic factor expression by electroacupuncture after transient focal cerebral ischemia. , 25 2 81 90, 0360-1293
Widenfalk J. Olson L. Thoren P. 1999Deprived of habitual running, rats downregulate BDNF and TrkB messages in the brain. , 34 3 125 132, 0168-0102
Widenfalk J. Lundstromer K. Jubran M. Brene S. Olson L. 2001Neurotrophic factors and receptors in the immature and adult spinal cord after mechanical injury or kainic acid. , 21 10 3457 3475, 1529-2401
Wooten G. F. Currie L. J. Bovbjerg V. E. Lee J. K. Patrie J. 2004Are men at greater risk for Parkinson’s disease than women? , 75 4 637 639, 0022-3050
Wu A. Molteni R. Ying Z. Gomez-Pinilla F. 2003 A saturated-fat diet aggravates the outcome of traumatic brain injury on hippocampal plasticity and cognitive function by reducing brain-derived neurotrophic factor., 119 2 365 375, 0306-4522
Wu D. C. Jackson-Lewis V. Vila M. Tieu K. Teismann P. Vadseth C. Choi D. K. Ischiropoulos H. Przedborski S. 2002Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. , 22 5 1763 1771, 1529-2401
Wu X. Chen P. S. Dallas S. Wilson B. Block M. L. Wang C. C. Kinyamu H. Lu N. Gao X. Leng Y. Chuang D. M. Zhang W. Lu R. B. Hong J. S. 2008Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. , 11 8 1123 1134, 1461-1457
Xia C. F. Boado R. J. Zhang Y. Chu C. Pardridge W. M. 2008Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson’s disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. , 10 3 306 315, 0109-9498X
B. Xin T. Zhao L. Hunter R. L. Chen Y. Bing G. 2010Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity. , 225 1-2, 43 51, 1872-8421
Xu G. Xiong Z. Yong Y. Wang Z. Ke Z. Xia Z. Hu Y. 2010Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum. , 167 1 174 184, 0306-4522
Xu Q. Park Y. Huang X. Hollenbeck A. Blair A. Schatzkin A. Chen H. 2010Physical activities and future risk of Parkinson disease. , 75 4 341 348, 0028-3878
Yasuhara T. Hara K. Maki M. Matsukawa N. Fujino H. Date I. Borlongan C. V. 2007Lack of exercise, via hindlimb suspension, impedes endogenous neurogenesis. , 149 1 182 191, 0306-4522
Yoon M. C. Shin M. S. Kim T. S. Kim B. K. Ko I. G. Sung Y. H. Kim S. E. Lee H. H. Kim Y. P. Kim C. J. 2007Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson’s rats. , 423 1 12 17, 0304-3940
Young D. Lawlor P. A. Leone P. Dragunow M. During M. J. 1999Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. , 5 4 448 453, 1078-8956
Yu H. Oh-Hashi K. Tanaka T. Sai A. Inoue M. Hirata Y. Kiuchi K. 2006Rehmannia glutinosa induces glial cell line-derived neurotrophic factor gene expression in astroglial cells via cPKC and ERK1/2 pathways independently. , 54 1 39 45, 1043-6618
Yu Y. P. Ju W. P. Li Z. G. Wang D. Z. Wang Y. C. Xie A. M. 2010Acupuncture inhibits oxidative stress and rotational behavior in 6-hydroxydopamine lesioned rat. , 1336No. 58 65, 0006-8993
Zesiewicz T. A. Evatt M. L. 2009Potential influences of complementary therapy on motor and non-motor complications in Parkinson’s disease. , 23 10 817 835, 1172-7047
Zhang Y. Xia Z. Hu Y. Orsi A. Rees D. 2008Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+. , 582 6 956 960, 0014-5793
Zhang Z. Miyoshi Y. Lapchak P. A. Collins F. Hilt D. Lebel C. Kryscio R. Gash D. M. 1997Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. , 282 3 1396 1401, 0022-3565
Zhou J. Zhang H. Cohen R. S. Pandey S. C. 2005Effects of estrogen treatment on expression of brain-derived neurotrophic factor and cAMP response element-binding protein expression and phosphorylation in rat amygdaloid and hippocampal structures. , 81 5 294 310, 0028-3835
Zhou Q. H. Boado R. J. Lu J. Z. Hui E. K. Pardridge W. M. 2010Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. , 38 4 566 572, 0090-9556
Zhuang X. Wang L. 2000Acupuncture treatment of Parkinson’s disease-a report of 29 cases. , 20 4 265 267, 0255-2922
Zigmond M. J. Cameron J. L. Leak R. K. Mirnics K. Russell V. A. Smeyne R. J. Smith A. D. 2009Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency. 15Suppl 3, S42 S45, 1353-8020